Guo Rongqi, Wang Rui, Zhang Weisong, Li Yangyang, Wang Yihao, Wang Hao, Li Xia, Song Jianxiang
Department of Thoracic Surgery, Affiliated Hospital 6 of Nantong University, Medical School of Nantong University, Nantong, PR China.
Department of Thoracic Surgery, Affiliated Hospital 6 of Nantong University, Yancheng Third People's Hospital, Yancheng, PR China.
Cancer Control. 2025 Jan-Dec;32:10732748251316604. doi: 10.1177/10732748251316604.
BACKGROUND: Macrophages are a critical component of the innate immune system, derived from monocytes, with significant roles in anti-inflammatory and anti-tumour activities. In the tumour microenvironment, however, macrophages are often reprogrammed into tumour-associated macrophages (TAMs), which promote tumour growth, metastasis, and therapeutic resistance. PURPOSE: To review recent advancements in the understanding of macrophage polarisation and reprogramming, highlighting their role in tumour progression and potential as therapeutic targets. RESEARCH DESIGN: This is a review article synthesising findings from recent studies on macrophage polarisation and reprogramming in tumour biology. STUDY SAMPLE: Not applicable (review of existing literature). DATA COLLECTION AND/OR ANALYSIS: Key studies were identified and summarised to explore mechanisms of macrophage polarisation and reprogramming, focusing on M1/M2 polarisation, metabolic and epigenetic changes, and pathway regulation. RESULTS: Macrophage reprogramming in the tumour microenvironment involves complex mechanisms, including phenotypic and functional alterations. These processes are influenced by M1/M2 polarisation, metabolic and epigenetic reprogramming, and various signalling pathways. TAMs play a pivotal role in tumour progression, metastasis, and therapy resistance, making them prime targets for combination therapies. CONCLUSIONS: Understanding the mechanisms underlying macrophage polarisation and reprogramming offers promising avenues for developing therapies to counteract tumour progression. Future research should focus on translating these insights into clinical applications for effective cancer treatment.
J Hematol Oncol. 2023-7-25
Biomed Pharmacother. 2024-8
Front Immunol. 2024
Front Immunol. 2025-7-3
Front Immunol. 2025-6-12
Front Oncol. 2024-7-18
Angew Chem Int Ed Engl. 2023-12-11